ClinicalTrials.Veeva

Menu

Middle Meningeal Artery Embolization for Chronic Migraine

Wake Forest University (WFU) logo

Wake Forest University (WFU)

Status

Not yet enrolling

Conditions

Migraine

Treatments

Procedure: Middle Meningeal Artery Embolization

Study type

Interventional

Funder types

Other

Identifiers

NCT07044648
IRB00131621

Details and patient eligibility

About

The main goal of this study is to find out how well middle meningeal artery coil embolization works for patients with recurrent chronic migraines that are not resolved with medication.

Full description

This study seeks to evaluate the therapeutic potential of middle meningeal artery coil embolization as an interventional strategy for patients with recurrent and pharmacoresistant chronic migraine. Middle meningeal artery embolization has recently gained recognition as a safe and effective intervention for the management of chronic subdural hematoma, demonstrating a low complication profile. The procedure achieves therapeutic effect by reducing or occluding arterial flow within the middle meningeal artery, thereby minimizing arterial dilatation and facilitating hematoma resorption over time.

Enrollment

70 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patient with diagnosis of migraine with or without aura, chronic migraine, unilateral or bilateral, moderate to severe intensity, 4-72 hours, familiar or sporadic, status migrainosus, primary or secondary
  • Patient who failed pharmacologic treatment (at least 2 failed drugs treatment for more than 3 months) or have considerable side effects
  • Patient with diagnosis of migraine and preference for embolization treatment
  • Clinical follow up of at least 3 months
  • Baseline computed tomography head (CTH) or MR brain which rule out additional intracranial pathology (patient with baseline intracranial pathology other than migraine will be excluded; see the exclusion criteria section below)
  • Presence of patent middle meningeal artery homolateral to the side of migraine

Exclusion criteria

  • Previous middle meningeal artery embolization for subdural hematoma
  • Previous craniotomy
  • Patients aged 17 years or younger.
  • Incomplete embolization of middle meningeal artery
  • Patient with baseline CTH or MR brain showing baseline intracranial pathology that can explain migraine

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

70 participants in 1 patient group

Middle Meningeal Artery Embolization
Experimental group
Description:
Participants receive middle meningeal artery embolization
Treatment:
Procedure: Middle Meningeal Artery Embolization

Trial contacts and locations

0

Loading...

Central trial contact

Hamad Farhat, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems